Trials / Completed
CompletedNCT00273936
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
Conditions
- Acute Leukemia
- Chronic Leukemia
- Multiple Myeloma
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Waldenstrom's Macroglobulinemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVN-944 capsules for oral administration |
Timeline
- Start date
- 2006-01-01
- First posted
- 2006-01-10
- Last updated
- 2011-08-04
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00273936. Inclusion in this directory is not an endorsement.